News | Artificial Intelligence | June 30, 2020

DiA Granted FDA Approvals for New COVID-19-related AI Solutions

DiA’s new AI-based LVivo RV enables rapid assessment of right ventricle dysfunction in COVID-19 patients, while LVivo Bladder supports clinicians with automated bladder volume analysis to minimize scan time and risk of infection

DiA’s new AI-based LVivo RV enables rapid assessment of right ventricle dysfunction in COVID-19 patients, while LVivo Bladder supports clinicians with automated bladder volume analysis to minimize scan time and risk of infection

June 30, 2020 — DiA Imaging Analysis, a leading provider of advanced AI-based solutions for ultrasound analysis, announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) 510(k) and a European CE mark for two additional AI-powered ultrasound analysis solutions.

  • LVivo RV is the first AI-based fully automated analysis of the heart’s right ventricle (RV) and can be used to diagnose and monitor right heart ailments in acute and chronic patients suspected to have RV injury, including those with COVID-19.
  • LVivo Bladder uses AI to deliver automated bladder volume measurements on ultrasound devices, significantly reducing patient scanning time and risk of infection.

Both solutions join DiA’s LVivo Toolbox, of now six FDA/CE-cleared AI-powered ultrasound solutions in total. The company was recently awarded a COVID-19-specific government grant from Israel’s Innovation Authority to accelerate access to its AI-based offerings in response to the COVID-19 pandemic.

“Physicians now face a host of new challenges and restrictions on the frontlines that underscores the critical role of ultrasound and value of having access to AI-powered solutions,” said Hila Goldman-Aslan, DiA’s CEO and Co-Founder. “With today’s FDA and CE approvals, DiA takes a big step toward strengthening our AI offerings for cardiac ultrasound while realizing our vision of making ultrasound analysis smarter and more accessible across a broader range of healthcare segments.”

There is growing evidence linking COVID-19 mortality and right ventricle heart failure. A study at Mount Sinai Morningside Hospital found that 31% of the patients hospitalized with COVID-19 had right ventricle failure, and that 41% of patients in this subset who died had signs of RV dilation or enlargement. By automatically providing quantified 2D analysis of the RV’s size and function, LVivo RV helps detect and monitor right heart failure. LVivo RV utilizes DiA’s flagship LVivo Artificial Intelligence platform to deliver faster, more accurate analysis while at the same time enabling clinicians to shorten patient scanning and evaluation time.

“The RV has always been very difficult to evaluate, due to its unique structure and location,” said Anthony M. Demaria, M.D., a leading cardiologist at University of California, San Diego (UCSD) Medical Center and a co-investigator of the multi-center study for LVivo RV. “This is further compounded by the complexity of the analysis itself, which relies on a combination of manual calculations and visual user input. LVivo RV is a welcome and very useful addition to clinicians’ toolbox for more quickly and effectively monitoring the right ventricle.”

Additional co-investigators of the study included David Rosenmann, M.D., and Shemi Carasso, M.D., at Israel’s Shaare Zedek Medical Center and Baruch Padeh Medical Center, respectively.

With LVivo Bladder, DiA extends its expertise beyond cardiology to abdominal ultrasound. Healthcare-associated urinary tract infections (UTIs) account for up to 40% of infections in hospitals and 23% of infections in the intensive care unit (ICU). LVivo Bladder enables ultrasound users to automatically and accurately measure bladder volume, which is currently done on cart-based systems manually or by dedicated bladder scanners. LVivo Bladder’s automated volume calculation turns any ultrasound device into a bladder scanner, minimizing patient scanning time and helping to prevent unnecessary catheterization to reduce the risk of infection.

For more information: www.dia-analysis.com

Related Content

An example of artificial intelligence on the GE Healthcare Vivid E95 system shown at ASE 2019 where the AI automatically pulls in an exam, identifies the left ventricle and myocardial boards and then calculates all the strain measurements in less than 10 seconds. While AI automation can greatly speed workflow, there are questions about the accuracy of AI for the next step in making diagnoses.  #ASE #ASE21 #ASE2021 #AI

An example of artificial intelligence on the GE Healthcare Vivid E95 system shown at ASE 2019 where the AI automatically pulls in an exam, identifies the left ventricle and myocardial boards and then calculates all the strain measurements in less than 10 seconds. While AI automation can greatly speed workflow, there are questions about the accuracy of AI for the next step in making diagnoses. 

Feature | Artificial Intelligence | September 08, 2021 | By Dave Fornell, Editor
Artificial intelligence is becoming best practice to support clinical decisions and help standardize echocardiography analysis for practices. AI, trained on millions of outcome-based data, can provide automation for operators to obtain highly accurate and precise measurements, to better detect and predict cardiovascular disease.
Webinar | Artificial Intelligence | August 12, 2021
Artificial intelligence is becoming best practice to support clinical decisions and help standardize echocardiography
An example of Viz.AI's pulmonary embolism AI application and mobile alert to the physician on-call. Viz.AI and Avicenna.AI Partner to Launch Artificial Intelligence Care Coordination for Pulmonary Embolism and Aortic Disease

An example of Viz.AI's pulmonary embolism AI application and mobile alert to the physician on-call.

News | Artificial Intelligence | July 21, 2021
July 21, 2021 — Artificial int...
Circle Cardiovascular Imaging Partners With DiA Imaging Analysis to Deliver AI-Based Cardiovascular Imaging Solutions
News | Artificial Intelligence | June 28, 2021
June 28, 2021 — Circle Cardiovascular Imaging Inc. and DiA Imaging Analysis Ltd.
Point of care ultrasound, POCUS, combined with artificial intelligence, can help improve echo image quality by inexperienced sonographers.

Getty Images

News | Artificial Intelligence | June 25, 2021
June 25, 2021 – COVID-19 changed everything in healthcare, and a benefit from this pandemic was a surge in innovation
GE is integrating artificial intelligence into most of its imaging and information technology software. AI can aid fast critical care decision making. Above left is the vScan Air wireless point-of-care ultrasound system. It integrates AI for immediate, automated assessment of a patient's ejection fraction, right.

GE is integrating artificial intelligence into most of its imaging and information technology software. AI can aid fast critical care decision making. Above left is the vScan Air wireless point-of-care ultrasound system. It integrates AI for immediate, automated assessment of a patient's ejection fraction, right.

Feature | Artificial Intelligence | June 10, 2021
The digital transformation of healthcare is underway, but it will advance further and faster if key stakeholders work
AI Med will present its Virtual Clinical Series: Imaging Built by Clinicians, for Clinicians, June 29-30, 2021.
News | Artificial Intelligence | June 09, 2021
June 9, 2021 — AI Med will present its...